AutoGenomics Inc.

AutoGenomics Inc. offers advanced diagnostic solutions for clinical laboratories, focusing on automated genetic testing and the analysis of biomarkers through its proprietary technology. Founded in 1999 and headquartered in Vista, California, AutoGenomics Inc. specializes in genetic testing solutions.

The company has secured funding through five different deals, with its most recent round occurring on January 11, 2013, where it raised USD 0. 170 mn. The current CEO is Keri Donaldson. AutoGenomics specializes in advanced diagnostic solutions for clinical laboratories, primarily through its flagship product, the INFINITI® system.

This system is designed for the processing of proprietary BioFilmChip® microarrays, enabling multiplex analysis of hundreds of biomarkers from a single sample. The INFINITI® system enhances laboratory productivity and workflow efficiency while providing precise, automated genetic testing that reduces operational costs per reportable result. Serving clinical laboratories across North America and select regions in Europe and Asia, AutoGenomics focuses on markets that require high-throughput genetic analysis for disease identification and treatment personalization. AutoGenomics generates revenue through the sale of its INFINITI® system and related BioFilmChip® microarrays, utilizing a B2B model with clinical laboratories.

Contracts are established for the purchase of testing systems and consumables essential for ongoing operations. Revenue streams encompass direct equipment sales, bulk microarray test purchases, and potential service agreements for maintenance and support, leveraging tiered pricing based on test volume and laboratory service scope. AutoGenomics plans to utilize the recent funding of USD 0. 165 mn raised in January 2013 to develop new products and expand its market reach.

The company is focusing on launching new diagnostic solutions by the end of 2014 and aims to enter additional international markets in Europe and Asia over the next two years.